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Adaptation of a standard extended-release
naltrexone (XR-NTX) protocol for rural reentering offenders with OUD
Michele Staton1,2* , Hannah K. Knudsen1,2, Sharon L. Walsh1,2, Carrie Oser2,3, Erika Pike2 and Michelle Lofwall1,2

Abstract
Background: Despite a growing body of empirical support for the effectiveness of extended-release naltrexone
(XR-NTX) to reduce opioid relapse among people with opioid use disorder (OUD) transitioning from a correctional
facility to the community, continuity of care following release remains challenging. This paper describes a researchbased adaptation of a state’s standard of care XR-NTX protocol using the ADAPT-ITT framework for delivery in a
non-traditional, non-treatment, community criminal justice setting (P&P office), as well as the expansion of services
by a local Federally Qualified Health Center (FQHC) provider who would, for the first time, be going to the jail and
P&P office to provide XR-NTX and related treatment.
Method: The present study focuses on the first seven phases (Assessment through Training) of the ADAPT-ITT
framework in the adaptation of the Department of Corrections (DOC) protocol in preparation for a pilot trial for
induction in a rural jail and during the transition to a rural community. Expert clinical review and focus groups with
key stakeholders in criminal justice supervision and the local providers in the FQHC informed the needed
adaptations to the existing XR-NTX protocol for initiation at the jail and ongoing administrations in the community.
Results: Findings from stakeholder focus groups, study team review, topical expert review, and a theater test
suggested that there were critical adaptations needed in both content and context at the patient and clinic level.
Conclusion: Health and justice officials should consider the need to tailor and adapt evidence-based approaches
for real-world locations that high-risk, justice-involved individuals visit in order to reduce barriers and increase
access to critically needed treatment for OUD.
Keywords: XR-NTX, Rural offenders, OUD, Community supervision

Background
While the opioid epidemic continues to pose a tremendous burden in a number of states, Kentucky has experienced particularly devastating public health and public
safety consequences associated with the non-medical use
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of prescription opioids and the insurgence of heroin and
illicit fentanyl (e.g., Faryar et al., 2017; Slavova, Rock,
Bush, Quesinberry, & Walsh, 2020; Victor, Walker, Cole,
& Logan, 2017). Despite the empirical support for efficacy of Federal Drug Administration (FDA)-approved
medications to treat opioid use disorder ([MOUD]; Lee
et al., 2015; Perry et al., 2013; Sharma et al., 2016; Syed
& Keating, 2013), only about 1 in 5 individuals with
OUD nationally receive any form of treatment and fewer
received medication (Saloner & Karthikeyan, 2015). Even
fewer receive treatment in resource-deprived areas, such
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as Appalachian Kentucky, due to the limitations of available services and stigma associated with seeking treatment (e.g., Oser & Harp, 2015).
Because an estimated 80% of individuals in the criminal justice system have a history of substance use and
about 20% report regular non-medical opioid use specifically (Bronson, Stroop, Zimmer, & Berzofsky, 2017), incarceration can serve as a critical window of opportunity
to initiate OUD treatment for affected individuals. However, the use of MOUD remains widely underutilized in
corrections. National surveys indicate that about half of
state jails and prisons use some form of MOUD, but
often limit this to pregnant women or management of
withdrawal (Friedmann et al., 2012; Grella, Ostile, Scott,
Dennis, & Carnavale, 2020; Oser, Knudsen, StatonTindall, Taxman, & Leukefeld, 2009). The use of MOUD
is often more restricted for individuals on community
supervision (i.e., probation and parole [P&P]), with some
P&P districts prohibiting the use of MOUD (Friedmann
et al., 2012). In addition, P&P officers typically have limited training on the potential benefits of MOUD (Mitchell et al., 2016). These challenges within the justice
system may contribute to limited treatment opportunities for individuals as they transition from correctional
settings to the community, particularly individuals reentering rural areas from jail who face limited access to
health and behavioral health care in general and limited
availability of MOUD, more specifically. These challenges are often exacerbated by lack of insurance coverage during the transition to the community, which may
also serve as a significant barrier to OUD treatment linkages, enrollment, and retention (Justesen et al., 2020).
Extended-release naltrexone (XR-NTX) reduces the
likelihood of opioid relapse among offenders re-entering
the community (Friedmann, Wilson, Hoskinson, Poshkus, & Clarke, 2018; Gordon et al., 2017; Lee et al.,
2016). As a sustained-release opioid antagonist, the primary advantage is that it should reduce challenges associated with adherence by providing 30 days of
medication, which can be advantageous during the community re-entry period following release (ASAM, 2015;
Lee et al., 2016). It also has no abuse liability, special
regulations, or provider training requirements. In a
proof-of-concept trial, Lee et al. (2015) found that XRNTX acceptance was high among males with OUD from
New York City jails with 88% initiating medication prior
to prison release; XR-NTX patients were significantly
less likely to return to opioid use after release. Medication adherence during community re-entry is critical,
however, in understanding outcomes. One study demonstrated that individuals transitioning from urban area
prisons in Baltimore were more likely to remain opioid
abstinent if they received six monthly XR-NTX administrations in the community post-release compared to
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those who received fewer community administrations
(Gordon et al., 2015). However, another study showed
no differences between XR-NTX alone and XR-NTX in
combination with patient navigation on opioid outcomes, largely attributed to low treatment adherence in
the community and high rates of re-incarceration at
follow-up (Farabee, Condon, Hallgren, & McCrady,
2020). The community re-entry period following release
can be stressful due to housing, income, transportation,
and relationship problems. Additionally, adherence to a
medication regime that requires developing a relationship with a new health care provider with at least
monthly clinic visits can also be challenging (Velasquez
et al., 2019).
The current study builds on the empirical evidence for
positive outcomes associated with XR-NTX for reentering offenders, but expands the work to consider an
innovative community model for ongoing treatment following jail release. In March 2015, state legislators
passed Senate Bill 192 (SB192), a comprehensive drug
policy that increased funding for MOUD (specifically
XR-NTX) in Kentucky prisons and jails (Dantzler, 2015).
The state Department of Corrections (DOC) Division of
Addiction Services worked closely with a national
pharmaceutical company and correctional health care
officials to develop a clinical protocol for screening and
administration of XR-NTX. Eligibility requirements included: an OUD diagnosis, within 60 days of anticipated
release, a negative urine drug screen before a 3-day oral
50 mg/day naltrexone challenge, and not being pregnant.
The DOC protocol included two XR-NTX administrations 1 month apart during incarceration with a referral
to a community case worker (social service clinician) for
coordination of and linkage to continued XR-NTX treatment and recovery services following release. The DOC
protocol was, however, limited to offenders who received
treatment in state Substance Abuse Programs (SAP),
which are modified therapeutic communities mostly
centralized in state prisons. Kentucky has 76 jails across
120 counties that house nearly 24,500 inmates daily
(Kentucky DOC, 2018); only 22 of these jails (29%) have
SAP programs with about 1600 treatment slots annually.
Thus, there was a significant need to adapt the DOC
protocol for XR-NTX administration to increase access
to the medication in a rural jail setting and to reduce
barriers to continued XR-NTX treatment upon community re-entry. The research-based adaptation, supported
by a federal research grant, is the focus of this paper.
Because adherence to XR-NTX can be challenging
post-release, adapting clinical XR-NTX continuity of
care protocols for delivery in settings where justiceinvolved individuals are likely to visit, such as the community P&P office, has the potential to reduce burdens
following jail release and improve MOUD adherence.
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The co-location of XR-NTX treatment in P&P offices
where individuals are expected to visit during re-entry
has not been examined, and thus requires significant adaptations to the existing state DOC XR-NTX standard
of care protocol (which is referred to as ‘DOC protocol’
hereafter). Furthermore, being attentive to the resources
and constraints of the rural Appalachian context where
the intervention is to be implemented is critically
important.
To systematically adapt the DOC protocol and fit the
needs of a population (individuals with OUD incarcerated in jail) (Rabin, Brownson, Haire-Joshu, Kreuter, &
Weaver, 2008), this study is guided by the ADAPT-ITT
framework. The ADAPT-ITT framework was originally
developed to guide the systematic adaptation of
evidence-based interventions (EBIs) targeting HIV risk
through eight sequential phases - Assessment, Decision,
Administration, Production, Topical experts, Integration, Training, and Testing (Wingood & DiClemente,
2008). Recent research using the ADAPT-ITT framework has emphasized its utility with HIV risk reduction
behavioral interventions (e.g., Khumsaen & Stephenson,
2017; Latham et al., 2010; Sullivan et al., 2014); however,
this is the first study to utilize the ADAPT-ITT framework for a medication administration protocol. The
ADAPT-ITT framework is well justified for this purpose
because it draws heavily on stakeholder feedback to better understand needed adaptions to both content of the
protocol, as well as context in the jail and in the rural
community. It also provides a systematic framework for
building upon the assessment of needed adaptation,
making decisions about those adaptations, and evaluating those changes in an iterative way prior to launching
a pilot trial. This paper describes the research-based
adaptation of the DOC protocol using the ADAPT-ITT
framework for delivery in a non-traditional, nontreatment, community criminal justice setting (P&P office), as well as the expansion of services by a local
FQHC provider who would, for the first time, be going
to the jail and P&P office to deliver comprehensive XRNTX care.

Method
The present study focuses on the first seven phases (Assessment through Training) of the ADAPT-ITT framework in the adaptation of the DOC protocol in
preparation for a pilot trial in a rural jail and P&P office
as part of a federally-supported research study. With implementation of the Assessment phase in February,
2019, the timeline for completion of all protocol adaptation phases was approximately 7 months, with pilot trial
testing beginning in Septembe 2019. This study was
reviewed and approved by the university Institutional
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Review Board and registered on ClinicalTrials.gov
(NCT03447743).
Study setting

The community setting for this study is one rural county
located in central Appalachia with a population of nearly
29,000. The county was selected because it is one of the
hardest hit areas by the opioid epidemic, and it is one of
the Appalachian counties identified as economically distressed with economic rankings in the worst 10% of the
counties in the nation (ARC, 2020). The county also includes strong community partners in the local jail, the
P&P office, and a rural FQHC who enthusiastically committed support for the study. The local county jail has a
daily census of approximately 150 and no current statesupported treatment (SAP program), but jail leadership
were interested in providing treatment for individuals in
custody. Based on previous studies, the majority of jail
inmates have a history of substance use, particularly opioid use (Staton et al., 2018). The selected county also
has a P&P field office, which organizationally falls under
the leadership of the Kentucky DOC. The majority of individuals on community supervision also have a history
of substance use-related offenses, and a common reason
noted for parole/probation violations was return to opioid use (Kentucky DOC, 2018). The partnership for this
project also includes a FQHC designated by the state of
Kentucky as a Rural Health Clinic, which also is a KY
DOC contracted site for community treatment. The
FQHC is in the same county as the jail. Specifically, this
FQHC administers XR-NTX (Vivitrol®) with counseling
and case management services to anyone released from
prison/jail who is interested in seeking OUD treatment.
Assessment

This first phase of the ADAPT-ITT process focuses primarily on assessing the needs of the target population
for the intervention including risks and logistical challenges with delivering the intervention (Wingood &
DiClemente, 2008). Consistent with other studies using
the ADAPT-ITT framework (Khumsaen & Stephenson,
2017; Munro-Kramer et al., 2020), focus groups were
used in the current study to provide the formative work
needed during the Assessment phase in order to assess
the needs of the target population and adapt intervention content. Two focus groups were conducted with
key stakeholder groups in March–April 2019, the first
with Department of Corrections (DOC) staff including
administrators, probation and parole officers, treatment
staff, and re-entry staff (n = 9), and the second with XRNTX health care providers and staff working at the
FQHC who would provide the MOUD at the jail and
post-release at either the P&P office or the FQHC (n =
5). Participation was offered to all DOC administrators
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and staff and all FQHC staff working with the target
population. The procedures were approved by the university Institutional Review Board, participants provided
written informed consent, and staff were reminded that
participation in the groups was completely voluntary.
Staff were not provided with a monetary incentive, but
refreshments were provided during the groups. Both
groups were conducted in private conference rooms, facilitated by the principal investigator (PI), and audiorecorded for transcription. The groups were guided by
semi-structured interview guides developed by the research team intended to assess attitudes toward MOUD,
available resources in the area, potential concerns about
XR-NTX, perceptions of client issues, and feedback on
possible assessment, evaluation, and medication administration procedures. Each group took approximately 1
hour. Transcripts from both focus groups were coded
and qualitatively analyzed using content analysis. Content analysis included specific focus on identified needs
of the target population (e.g., OUD diagnosis, medically
eligible to initiate medication, re-entry challenges to engaging in treatment) and necessary changes to the DOC
protocol to ensure continuity of care in the community.
Decision

The Decision phase of the ADAPT-ITT process typically
involves a review of the evidence for the EBI, deciding
on the EBI for the target population, and making decisions about needed adaptations to the EBI for the proposed population (Wingood & DiClemente, 2008). The
empirical literature on delivery of XR-NTX for justiceinvolved individuals in transition from jail to the community provided the foundation for the current study
(e.g., Friedmann et al., 2018; Gordon, Kinlock, et al.,
2017; Lee et al., 2016). In addition, documentation including the coded transcripts from the focus groups and
content analysis were used to inform decisions about
specific recommended adaptations to content, delivery
strategies, and frequency/method of contact.
Administration

The Administration phase of the ADAPT-ITT process
involves a pilot test of the adapted intervention, typically
referred to as a “theater test” (Wingood & DiClemente,
2008). The theater test involves a demonstration, or walk
through, of the adapted intervention with individuals either from the target population or individuals who can
simulate the needs and behaviors of the target population. The adapted version underwent a “theater test” of
all study procedures in a private room in the jail (screening, medical evaluation, initial XR-NTX administration
procedures) and in a private room in the P&P office (ongoing community XR-NTX administration) with an experienced physician co-investigator (MRL) simulating
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the role of the patient. With more than 15 years of clinical and research experience with individuals with OUD,
our volunteer realistically portrayed different scenarios
for the research staff and FQHC clinical team while
walking through each section of the adapted protocol.
The research study coordinator and PI were present during the theater test to take notes on each section of the
protocol for additional modifications.
Production and topical expert review

The Production phase includes finalizing a working draft
of the adapted protocol with a focus on maintaining the
critical elements of XR-NTX delivery with modifications
tailored to fit the needs of the client population (content) during the period of transition between jail to the
community (context). This phase of ADAPT-ITT is
closely followed by the Topical Expert review which includes review of the protocol by a designated consultant
with expertise in the scientific area (Wingood & DiClemente, 2008). For the current study, notes from the theater test were incorporated into the adapted protocol
and reviewed by the study team, including two coinvestigators (MRL, SLW) with extensive clinical and research experience with MOUD. Feedback from the team
was used to produce a more refined version of the XRNTX protocol for review by a paid study consultant
(Topical Expert). The Topical Expert was a physician researcher from an outside University with previous and
on-going clinical and research trial expertise involving
the delivery of XR-NTX during incarceration as individuals prepare for community re-entry.
Integration

The Integration phase of ADAPT-ITT includes incorporating all of the suggested changes during the Topical
Expert review into a more refined draft of the adapted
protocol. Integration of all feedback should be done with
an eye to maintaining the core components of the protocol and tailoring specifically to the target population
(Wingood & DiClemente, 2008). For the current study,
feedback from the topical expert and study team was
then integrated into the final draft of the adapted XRNTX protocol. The PI, physician Co-I, and study coordinator met with key stakeholders from the partnering jail
and P&P office, as well as the FQHC clinical team to review the protocol and assess feasibility.
Training

Training is the last ADAPT-ITT phase before pilot testing. This phase typically includes all study personnel including clinical and research staff (Wingood &
DiClemente, 2008). One full-day interactive training session was conducted with research staff on the adapted
XR-NTX protocol for the current study.
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Results
Assessment

The first focus group, which included representatives
from the DOC, indicated there was general agreement
that, despite seeing an increase in non-medical use of
buprenorphine in the area (including by injection), individuals were usually allowed to continue needed and
prescribed MOUD while on community supervision. Regarding initiating medication prior to jail release and
continuing medication during supervision, one of the
significant challenges noted by the group was the feasibility of identifying potential participants. The local jail
is a regional facility and many individuals housed there
transition to supervision in surrounding counties, making continuing care with the local FQHC infeasible. The
group noted concerns around identifying someone who
is eligible for release to supervision and their actual release date within the 30-day window for XR-NTX administration. Also, because the re-entry period can be
stressful and chaotic, revocation was common (and perhaps expected) if underlying SUD went untreated or inadequately treated. Therefore, identification of potential
participants may need to expand to those serving a short
sentence under discretionary detention (graduated sanction) or home incarceration.
Other concerns about meeting the needs of participants were raised in this focus group. One focus group
participant noted, “Transportation is absolutely a problem around here,” a sentiment that was shared by the
majority of the group. This statement highlighted expectations that providing ongoing medication administration at P&P rather than requiring a separate trip to a
community clinic could significantly reduce barriers to
retaining individuals on XR-NTX. DOC staff also emphasized the importance of participants in the pilot receiving counseling as part of their treatment with the
clinic provider because they noted that a number of individuals on their caseloads had co-occurring mental
health issues. Thus, staff strongly encouraged coordination of the XR-NTX administration appointment with
counseling and case management sessions to coincide
with the report day for study participants. DOC staff
agreed they would need to maintain flexibility on reporting days in order to ensure that the clinic providers
could come to the P&P office on these same days to provide care.
Finally, DOC staff mentioned stigma around MOUD
in general and some misconceptions around XR-NTX
specifically in the community and among professionals
including jail staff. One respondent noted, “That negativity and stigma can go through the whole jail and can
really affect whether people want to participate in this.”
The group discussed the importance of providing education about XR-NTX for both the jail staff and medical
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personnel, in addition to individuals participating in the
study. One respondent noted, “I think it would be helpful if we did some type of education for the staff there
[at the jail], especially the medical because I’m sure
they’re going to be probably fielding some general questions. If they don’t support it, I think that that could
really cause people not to want to participate.” Overall,
DOC staff felt like jail staff and medical providers would
be receptive to additional XR-NTX education during
study implementation.
A second focus group was completed with health care
providers and staff at the partnering FQHC to understand better their standard of care, client needs, challenges of initiating and sustaining XR-NTX treatment,
and ancillary case management and counseling services.
Findings indicated that the clinic XR-NTX standard of
care involved an assessment with a detailed medical and
psychosocial history, urine drug screen, and laboratory
bloodwork (metabolic panel, liver function tests,
complete blood count). If patients do not have health insurance, staff work with patients to enroll them in Medicaid and obtain XR-NTX pre-authorization. All
patients are provided with case management and are expected to participate in counseling sessions. Whenever
possible, these appointments are all scheduled for the
same day as the XR-NTX administration to reduce the
burden of additional travel for patients. As long as patients are eligible (e.g., opioid negative urine sample, not
in liver failure), clinic staff attempt to schedule patients
the day after the medical evaluation for the oral naltrexone challenge (50 mg, 30-min wait period) and XR-NTX
administration. At the time of the focus group, staff were
only able to operate within their physical clinic location
and 14 patients on XR-NTX was considered a “pretty
big” clinic caseload.
In adapting their procedures for providing XR-NTX in
the jail, FQHC staff stressed the importance of coordination with the jail administration to be able to provide
all services (e.g., counseling, case management) in a private location. They felt strongly that maintaining confidentiality was critical in the jail setting and having the
space to meet with a patient one-on-one was necessary.
One of the identified challenges was that clinic staff did
all of their charting electronically, which would not be
feasible in the jail due to computer and internet restrictions. It was agreed that paper copies of forms could be
collected for the jail medical visits and later entered into
their electronic health record. Finally, another potential
concern was the expectation that jail staff may negatively
view using medications, which could be challenging for
the study. With additional education and training, however, FQHC staff noted that views around medications
can change, which also may be an important consideration for the study. One staff noted, “After I worked with

Staton et al. Health and Justice

(2021) 9:4

a physician who prescribed Suboxone®, my view of Suboxone® is way different than it used to be.” Similar to the
DOC staff focus groups, the importance of education
around XR-NTX to reduce stigma was an important
finding.
Decision

Decisions related to initial DOC protocol adaptations
were grounded in the stakeholder focus group findings,
the empirical literature, ASAM (2015) guidelines for XRNTX administration, and medication guidelines from
the FDA package label (https://www.vivitrol.com/
content/pdfs/medication-guide.pdf). Adaptations to the
DOC protocol included more detailed procedures for
screening, medical evaluation, and XR-NTX administration, as well as attention to culturally relevant language
and examples to target rural Appalachian individuals
with OUD (as shown in Table 1).
In addition, because of time and travel required to
both the jail (for the clinical staff) and the P&P office
following release (for the individual), protocol decisions
included ensuring counseling and case management on
the same day as the XR-NTX administration for individuals enrolled in the study.
Administration

Overall, the walk through of the adapted protocol during
the theater test indicated that the critical components of
screening, assessment, medical evaluation, medication

Page 6 of 11

initiation, and continuity of care were consistent with
the standard of care in addressing the volunteer’s needs.
The theater test did reveal specific areas of training
needs for the clinical team to adapt their traditional clinical practice to a clinical trial. For example, completion
of each of the protocol forms to determine participant
eligibility for the trial required more training on attention to detail and documentation in the jail (as compared to what was needed in the clinic environment). As
a result, additional questions were added to the medical
history and assessment to document OUD.
Production and Topical Expert review

A more refined version of the adapted protocol was produced based on the theater test findings. Each section of
the protocol was clearly delineated by sections (e.g.,
Screening and Recruitment, Medical Evaluation, Initial
Injection, Community Injections) and included procedures for both research and clinical staff. Each section of
the refined protocol included step-by-step procedures, as
well as relevant research forms for documentation.
Reviews by both our study team and Topical Expert
yielded additional suggestions during this stage of protocol refinement. One change included supporting the recommended change from the original protocol related to
the oral naltrexone challenge of 50 mg for 3 days to 12.5
mg 2 h before the XR-NTX injection, which was also
supported by empirical research on XR-NTX administration with correctional populations at re-entry

Table 1 Initial modifications to protocol based on focus groups
DOC Protocol

XR-NTX Pilot Adaptations For Research Study

Patient identification

Participant in DOC Substance Abuse Program (SAP),
modified therapeutic community during
incarceration

Individuals in jail preparing for release; screening
protocols to identify transition to supervision in target
county and release dates (including court dates and
pleas)

Patient eligibility

Only state inmates in state-funded jail and prison
All individuals (regardless of classification) in one target
SAP programs with OUD who meet eligibility criteria rural county jail with an OUD transitioning to
community supervision in the same county who meet
eligibility criteria

OUD and physical dependence
determination

Assessment of OUD through state data collection
system, includes DSM criteria; negative urine drug
screen

Additional tools were included in screening and
assessment including DSM5 checklist assessment for
OUD, negative opioid urine screen, and Clinical Opioid
Withdrawal Scale (COWS) total score indicating no
withdrawal

Oral naltrexone dosing, First XR-NTX
administration and other ancillary
services during incarceration

XR-NTX administered by corrections health care and
any ancillary services provided through SAP (during
incarceration) after taking 50 mg oral naltrexone
once daily for 3 days

XR-NTX administered by one community clinic partner
in the jail; session includes counseling and case
management. XR-NTX injection given two hours after
tolerating single dose of oral naltrexone 12.5 mg

On-going XR-NTX administrations in
the community

Referrals made to community providers based on re- Second XR-NTX administration scheduled at the clinic
entry plan
[comparison condition] or at the P&P office [experimental condition] (coordinated with report days) based
on random assignment

Patient documentation

Medical evaluation results (including laboratory
Medical evaluation results, XR-NTX administration notes,
results) and XR-NTX administration notes included in counseling and case management notes recorded on
individuals’ medical record at the facility
paper forms in the jail and transferred to electronic
medical record upon return to the clinic
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(Friedmann et al., 2012; Gordon, Vocci, Fitzgerald,
O’Grady, & O’Brien, 2017; Lee, Friedmann, et al., 2015;
Lincoln, Johnson, McCarthy, & Alexander, 2018). This
change also required commitment from the FQHC clinical team to change their standard of care protocol from
a single 50 mg dose followed by observation to ensure
no precipitated withdrawal for 30 min to a single 12.5
mg dose with 2-h observation period for research study
participants only, which was supported as the 2-h wait
period was an ideal time to deliver counseling and initiate case management services prior to jail release.
Other important findings from this phase included
clarity on the timeframe for community XR-NTX administration if an individual passed the target window
for the second administration following jail release (~ 30
days). The goal was to retain patients on XR-NTX if the
participant desired it and it remained medically safe to
continue. Thus, in the case of suspected or confirmed
lapse/relapse, the protocol required a negative opioid
urine drug screen, no recent self-report of opioid use,
12.5 mg oral naltrexone challenge tolerance (if needed as
determined by clinical judgement), and a clinical opioid
withdrawal scale (COWS) score < 8 prior to considering
the next XR-NTX administration.
Integration

Feedback from the Topical Expert and study team was
then integrated into the final draft of the adapted XRNTX protocol. The PI, physician Co-I, and study coordinator met with key stakeholders from the partnering jail
and P&P office, as well as the FQHC clinical team to
walk through the protocol to assess feasibility. At this
meeting, final decisions were made about logistics (e.g.,
which rooms to use, channels of communication, etc.) in
both the jail and the P&P office. One final review of the
completed protocol was conducted by the research team
prior to launching training for the pilot trial.
Training

The Training phase included education for both research staff and the FQHC team. One full-day interactive training session was conducted with research staff
on the adapted XR-NTX protocol. Training material was
both didactic (e.g., overview of key content by the PI)
and interactive (e.g., role play with volunteers as practice
sessions) and primarily focused on confidentiality and
informed consent, recruitment and screening procedures, and data collection procedures at baseline and in
the community at 3 months post-release from jail. A
separate one-day training was conducted with the FQHC
health care team including the nurse practitioner, registered nurse, therapist, case manager, medical records
staff, and clinic administrators. The training was led by
the physician Co-I and included a didactic presentation
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on each section of the adapted protocol with specific
focus on procedures in the medical evaluation and XRNTX administration sessions. Training for health care
providers also included a focus on research documentation, medication shipment and storage, and maintaining
data records. All research and clinical team members
were included on the IRB protocol and completed required protection of human subjects and NIH Good
Clinical Practice trainings. The study physician Co-I,
who also serves as the Medical Monitor, provided one
additional half-day training on assessing, documenting,
and reporting adverse events. Finally, in preparation for
the pilot trial launch, a two-hour training was also provided for officers in the partnering P&P office in order
to raise awareness about the study, discuss XR-NTX administration, provide details about the adapted XR-NTX
protocol and logistics, and answer any questions.

Discussion
Justice-involved individuals with a history of OUD are
among the most vulnerable because they often experience sustained abstinence with subsequent loss of opioid
tolerance during incarceration and, without linkage to
treatment, they are at high risk for overdose during
community re-entry. This study is grounded in the empirical evidence for XR-NTX for re-entering offenders,
but expands the work to examine an innovative model
to support continuity of care with XR-NTX after jail release by co-locating MOUD treatment within the P&P
office. This paper describes the first seven steps of the
ADAPT-ITT framework for the research-based adaptation of the DOC protocol for XR-NTX administration in
substance use treatment programs to a non-traditional,
non-treatment, re-entry model of care (jail and P&P office) in a rural community. This is the first study to
utilize the ADAPT-ITT framework for a medication administration protocol.
Findings from stakeholder focus groups, study team
review, topical expert review, and a theater test suggested that there were critical adaptations needed at the
patient and clinic level. In the original DOC protocol,
potential patients are identified through existing SAP
programs within prisons, jails, and community custody
settings. While the number of treatment slots have
grown in recent years in the state, DOC currently has
the capacity to treat about a quarter of inmates with a
history of substance use (CJKTOS, 2019). Thus, to implement the adapted XR-NTX protocol in a jail without
a SAP program required specific adaptations for patient
identification and eligibility not currently included in
DOC protocol. Other critical adaptations included identifying a target release date in order to administer XRNTX while incarcerated and also making sure individuals were within a target window for release to the
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community. The pilot trial test of the adapted protocol
requires a flexible target window in order to accommodate administering XR-NTX prior to release for both
state inmates (with set parole dates to the community)
and county inmates (usually people in jail with less predictable release dates who are then placed on probation).
Finally, because individuals approached about the pilot
study may be hearing about XR-NTX for the first time,
the screening procedures and medical evaluation included education about XR-NTX benefits and potential
side effects.
The DOC protocol for the administration of XR-NTX
included counseling provided through the state SAP
programs and case management provided through a social service clinician in the P&P office following release.
Because the adapted protocol will be implemented in a
non-treatment jail setting, critical modifications were
needed by the community partner in order to provide
counseling and case management during the same session as XR-NTX initial and follow-up administration in
order to reduce additional travel burden for clinic staff
and volunteers. In practice, once a participant is cleared
for XR-NTX induction following the medical evaluation,
this includes a therapist and case manager accompanying the nurse to the jail. Following administration of the
oral challenge of naltrexone, the therapist and case manager meet with the participant prior to receiving XRNTX. Working with one community provider will also
allow continuity of care from the jail (medical evaluation
and XR-NTX induction) to the community (on-going
medication administrations post-release always coupled
with counseling and case management at the medication
administration visit).
Lessons learned

DOC protocol adaptations were primarily related to context and content. Initiation of XR-NTX is guided by federal and state guidelines in best practices which include
screening for OUD, a medical evaluation with laboratory
tests (urine toxicology, metabolic panel, liver function
tests, complete blood count, pregnancy testing), and lack
of opioid physical dependence (SAMHSA, 2020). Each
of these core components were maintained in the
adapted protocol. The primary differences are noted in
patient recruitment, medication induction doses, urine
drug screening requirements (became more lenient
allowing for non-opioid tests to be positive) and the continuity of care from jail to the community.
With regard to patient recruitment, it is important to
recognize the stigma around MOUD in rural areas may
affect participation. It was noted in both stakeholder
focus groups that stigma around non-medical opioid use
in general, as well as MOUD treatment (and XR-NTX
specifically), is very common in this rural area –
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including among a number of professional organizations
(including criminal justice staff). This has been consistently noted in the literature for criminal justice organizations, particularly P&P and jails (e.g., Bunting, Oser,
Staton, Eddens, & Knudsen, 2018; Friedmann et al.,
2012). Being mindful of the potential stigma around
medications during the recruitment and community retention is important, as well as increasing education for
participants and stakeholders on the benefits of
medications.
DOC focus group findings also suggested that re-entry
to the community from jail is a high-risk and chaotic
period for justice-involved individuals. It is possible that
life events – such as finding safe housing or stable employment – may supersede the perception of the importance of treatment and negatively impact adherence to
XR-NTX post-release, which has been noted elsewhere
(Velasquez et al., 2019). In addition, if an individual relapses or engages in criminal activity after release, he/
she may abscond from supervision – making XR-NTX
administration in the community supervision office not
feasible. These issues of feasibility and acceptability are
critical to monitor during the pilot trial test in this nontraditional, non-clinical environment in preparation for
a larger clinical trial.
Partnering with a local FQHC as the health care provider for the study is a tremendous asset, particularly in
ensuring familiarity with the clinical protocol for XRNTX administration. A main advantage is the potential
to enhance the continuity of care from the medical
evaluation and initial XR-NTX administration in the jail
to ongoing XR-NTX administrations and supported services in the community. Challenges noted during the
planning process included participation in the research
trial as possibly burdensome for clinic staff considering
their standard clinical responsibilities. Specifically, in
addition to patient care (nurses) and therapeutic caseloads (therapist and case manager), FQHC clinic team
members had to travel to the jail for initial visits with
the participants, as well as complete additional forms for
OUD assessment and documentation, medical histories,
and study protocol adherence checklists. While this required additional training by the research team, having a
shared vision for the success of the pilot trial was the
foundation for ensuring resource allocation (e.g., supporting clinic staff salary) to best balance the research
trial in the context of day-to-day clinical operations.
Clinical staff also received additional professional development training on managing clinical trials, which was
useful for their future work. In addition, balancing the
workload with the research staff so that they assist with
screening procedures and monitoring participant forms
and documentation to assist with potential burden on
the clinical team was also beneficial.

Staton et al. Health and Justice

(2021) 9:4

Along these lines, it is also important to note that
most clinical trials take place in laboratory or clinical research environments. Small community FQHCs and
criminal justice settings, such as jails and community
supervision offices, are less “controlled” from a research
perspective and may be more vulnerable to policy level
changes that affect study enrollment. Examples include
closing the jail and/or P&P offices due to financial constraints, reorganizations, or public health crises (e.g.,
COVID-19 pandemic). In addition, in controlled laboratory trials, study treatment cost is often covered by the
project, while in real-life settings, it can be more heavily
impacted by health plan coverage (which may limit
treatment access).
Limitations

The primary limitation of this descriptive level qualitative research is the lack of generalizability beyond the
stakeholders of two professional groups (corrections and
health care staff) in one small rural community in Appalachia. While recognizing this limitation, focus group
feedback was used primarily for the purpose of intervention adaptation in this study rather than a broader focus
on qualitative assessment. Our reliance on a systematic
framework to guide the adaptation process enhances the
rigor of study qualitative methods. The current study is
targeted to administration of XR-NTX, which limits
generalizability to other MOUDs including buprenorphine and methadone. However, the use of the ADAPTITT framework provides a systematic and iterative
process that could be replicated in other settings, for
other evidence-based medications such as buprenorphine, and for other target populations. Future research
should also include justice-involved individuals during
the planning and adaptation process, a potential limitation in the current study and a notable gap in the
broader literature (Puglisi, Bedell, Steiner, & Wang,
2019).

Conclusion and next steps
Despite these limitations, the significance of this study
for health and justice officials lies in the response to the
opioid crisis in rural Appalachia, the increased vulnerability of rural individuals with OUD, and the dearth of
available and accessible evidence-based treatment which
can be addressed through an innovative partnership between a jail, local P&P, and a clinic. This paper overviews study activities and findings through the first
seven phases of the ADAPT-ITT framework. Next, we
will complete the final ADAPT-ITT phase, Testing,
which involves launching the pilot randomized clinical
trial (RCT) to screen, assess, and medically evaluate eligibility for XR-NTX. The pilot RCT will also examine
the continuation of XR-NTX from induction in the jail
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to on-going community administrations in one of two
test sites following jail release. The pilot RCT will inform
whether co-locating treatment in real-world criminal
justice settings, like P&P offices [experimental arm], can
successfully reduce barriers to on-going community
treatment (such as transportation), while also signifying
support for treatment engagement from the criminal
justice system compared to on-going treatment at the
clinic [comparison condition]. Findings from the pilot
trial have the potential to contribute to the OUD treatment field by advancing knowledge on innovative service
delivery models to reduce high-risk opioid use and related health disparities among hard-to-reach, underserved justice-involved populations.
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